JP7233147B2 - リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 - Google Patents

リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 Download PDF

Info

Publication number
JP7233147B2
JP7233147B2 JP2022539639A JP2022539639A JP7233147B2 JP 7233147 B2 JP7233147 B2 JP 7233147B2 JP 2022539639 A JP2022539639 A JP 2022539639A JP 2022539639 A JP2022539639 A JP 2022539639A JP 7233147 B2 JP7233147 B2 JP 7233147B2
Authority
JP
Japan
Prior art keywords
fibroblasts
adm
cells
pharmaceutical composition
hhex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022539639A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022186349A5 (https=
JPWO2022186349A1 (https=
Inventor
貴紘 岩宮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metcela Inc
Original Assignee
Metcela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcela Inc filed Critical Metcela Inc
Publication of JPWO2022186349A1 publication Critical patent/JPWO2022186349A1/ja
Publication of JPWO2022186349A5 publication Critical patent/JPWO2022186349A5/ja
Priority to JP2023020860A priority Critical patent/JP2023058660A/ja
Application granted granted Critical
Publication of JP7233147B2 publication Critical patent/JP7233147B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022539639A 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 Active JP7233147B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023020860A JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021034018 2021-03-04
JP2021034018 2021-03-04
JP2021034016 2021-03-04
JP2021034016 2021-03-04
PCT/JP2022/009205 WO2022186349A1 (ja) 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020860A Division JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2022186349A1 JPWO2022186349A1 (https=) 2022-09-09
JPWO2022186349A5 JPWO2022186349A5 (https=) 2023-02-01
JP7233147B2 true JP7233147B2 (ja) 2023-03-06

Family

ID=83155368

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022539639A Active JP7233147B2 (ja) 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物
JP2023020860A Withdrawn JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023020860A Withdrawn JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Country Status (8)

Country Link
US (1) US20240148795A1 (https=)
EP (1) EP4302771A4 (https=)
JP (2) JP7233147B2 (https=)
KR (1) KR20230154177A (https=)
AU (1) AU2022231584A1 (https=)
CA (1) CA3211113A1 (https=)
IL (1) IL305069A (https=)
WO (1) WO2022186349A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
JP2025515887A (ja) 2022-11-11 2025-05-20 エルジー エナジー ソリューション リミテッド 負極活物質、これを含む負極、これを含む二次電池、および負極活物質の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020045547A1 (ja) 2018-08-29 2020-03-05 株式会社メトセラ 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020045547A1 (ja) 2018-08-29 2020-03-05 株式会社メトセラ 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUNWORTH ,W. P. et al.，Adrenomedullin stabilizes the lymphatic endothelial barrier in vitro and in vivo.，Peptides，2008年，29，pp.2243-2249
KACH, J. et al.，Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedull，Am. J. Physiol. Lung Cell Mol. Physiol.，2013年，304 (11)，L757-764
KONG, F. et al.，Exosomal adrenomedullin derived from cancer-associated fibroblasts promotes lipolysis in adipose tis，Gut，2018年，67 (12)，pp.2226-2227

Also Published As

Publication number Publication date
WO2022186349A1 (ja) 2022-09-09
JP2023058660A (ja) 2023-04-25
EP4302771A1 (en) 2024-01-10
AU2022231584A1 (en) 2023-09-07
KR20230154177A (ko) 2023-11-07
IL305069A (en) 2023-10-01
US20240148795A1 (en) 2024-05-09
EP4302771A4 (en) 2025-04-02
CA3211113A1 (en) 2022-09-09
JPWO2022186349A1 (https=) 2022-09-09

Similar Documents

Publication Publication Date Title
Rieder et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis
Chen et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair
US20120093885A1 (en) Therapeutic vesicles
JP7428389B2 (ja) 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団
JP2007143554A (ja) 細胞移植方法及び試薬
JP2013542178A (ja) 心臓修復のための骨髄由来ｃｄ２７１前駆細胞
JP7233147B2 (ja) リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物
CN114164174A (zh) 含有适合用于缺血性疾病治疗的细胞的细胞群体的体外增殖方法
Diller et al. Endothelial progenitor cells in pulmonary arterial hypertension
Cao et al. Combined hypoxia inducible factor-1α and homogeneous endothelial progenitor cell therapy attenuates shunt flow–induced pulmonary arterial hypertension in rabbits
Guo et al. Young human PRP promotes the rejuvenation of aged bone marrow mesenchymal stem cells and the therapeutic effect on ischemic heart disease
Suzuki et al. The reduction of hemodynamic loading assists self-regeneration of the injured heart by increasing cell proliferation, inhibiting cell apoptosis, and inducing stem-cell recruitment
CN117120063A (zh) 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物
US20080317720A1 (en) Fat-Derived Progenitor Cell and Use Thereof
US20200011855A1 (en) COMPOSITION FOR PREVENTING OR TREATING LIVER FIBROSIS OR CIRRHOSIS, COMPRISING EXPRESSION OR ACTIVITY ENHANCER OF TIF1y AS ACTIVE INGREDIENT
Xing et al. Localized COUP‐TFII pDNA Delivery Modulates Stem/Progenitor Cell Differentiation to Enhance Endothelialization and Inhibit Calcification of Decellularized Allografts
RU2800644C2 (ru) Способ получения фибробластов и г-ксф-положительная фибробластная масса
WO2025086234A1 (zh) Cd133阳性内皮样干细胞在制备促进内皮细胞分化和血管再生的药物的应用
WO2022138955A1 (ja) 動脈解離の治療剤
Altrieth Endothelial and Stromal Cell Contributions to Salivary Gland Injury and Repair
Abbas An Essential Role for Skeletal Muscle Progenitor Cells in Response to Ischemia in Vascular Disease
Nie et al. MiR-93-5p in BM-MSCs-derived exosomes amelio-rates renal fibrosis by affecting macrophage polar-ization
Pasquinelli et al. Restenosis in hemodialytic fistulas and chronic kidney disease-associated vascular disease: two pathologies driven by metakaryotic stem cells
JP4083024B6 (ja) 細胞移植方法及び試薬
Marsboom et al. Vascular Repair and Regeneration by Endothelial Progenitor Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220707

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220707

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230214

R150 Certificate of patent or registration of utility model

Ref document number: 7233147

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250